var data={"title":"Paliperidone: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Paliperidone: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/250813?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=paliperidone-patient-drug-information\" class=\"drug drug_patient\">see &quot;Paliperidone: Patient drug information&quot;</a> and <a href=\"topic.htm?path=paliperidone-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Paliperidone: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50629645\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Atypical Antipsychotics Safety Review</span>\n      <span class=\"collapsible-date\">September 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Health Canada has reviewed the potential risk of sleep walking and sleep-related eating disorder with the use of atypical antipsychotics and concluded there is a link between these adverse reactions and the use of these medications. Health Canada has recommended to update the product safety information for all atypical antipsychotics to include these adverse reactions.</p>\n        <p style=\"text-indent:0em;\">Further information may be found at https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/atypical-antipsychotics-assessing-potential-risk-sleep-walking-sleep-related-eating-disorder.html.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709193\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Increased mortality in elderly patients with dementia-related psychosis: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Paliperidone is not approved for the treatment of patients with dementia-related psychosis.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3981432\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Invega;</li>\n      <li>Invega Sustenna;</li>\n      <li>Invega Trinza</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5941023\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Invega;</li>\n      <li>Invega Sustenna;</li>\n      <li>Invega Trinza</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3982373\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Second Generation (Atypical) Antipsychotic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3982410\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Schizoaffective disorder:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Usual: 6 mg once daily (administered in the morning in clinical trials); titration not required, though some may benefit from lower or higher doses (range: 3 to 12 mg daily). If exceeding 6 mg daily, increases of 3 mg daily are recommended at intervals of more than 4 days, up to a maximum of 12 mg daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Monthly IM: <b>Note:</b> Prior to initiation of monthly IM paliperidone, for patients naive to oral paliperidone or oral or injectable risperidone tolerability should be established with a test dose of oral paliperidone or oral risperidone. Previous oral antipsychotic regimen can be gradually discontinued at the time of initiation of monthly IM paliperidone. <b>Dosing based on paliperidone palmitate (US labeling) or paliperidone base (Canadian labeling).</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Initiation of therapy:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial: 234 mg (as palmitate) or 150 mg (as base) on treatment day 1 followed by 156 mg (as palmitate) or 100 mg (as base) 1 week later with both doses administered in the deltoid muscle. The second dose may be administered 4 days before or after the weekly time point.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance: Following the 1-week initiation regimen, adjust the dose based on response and tolerability and begin a maintenance dose of 39 to 234 mg (as palmitate) or 25 to 150 mg (as base) every month administered in either the deltoid or gluteal muscle (the 39 mg dose [as palmitate] was not studied in schizoaffective disorder trials). The monthly maintenance dose may be administered 7 days before or after the monthly time point.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Conversion from oral paliperidone to monthly IM paliperidone:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initiate monthly IM paliperidone as described using the 1-week initiation regimen. Patients previously stabilized on oral doses can expect similar steady state exposure during maintenance treatment with monthly IM paliperidone using the following conversion:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral extended-release dose of 12 mg daily, then IM maintenance dose of 234 mg (as palmitate) or 150 mg (as base) monthly</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral extended-release dose of 9 mg daily, then IM maintenance dose of 156 mg (as palmitate) or 100 mg (as base) monthly</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral extended-release dose of 6 mg daily, then IM maintenance dose of 117 mg (as palmitate) or 75 mg (as base) monthly</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral extended-release dose of 3 mg daily, then IM maintenance dose of 39 to 78 mg (as palmitate) or 25 to 50 mg (as base) monthly</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Conversion from other oral antipsychotics to monthly IM paliperidone:</i> There is no systematically collected data to address switching patients from other oral antipsychotics to monthly IM paliperidone.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Switching from other long-acting injectable antipsychotics (at steady-state) to monthly IM paliperidone:</i> Initiate monthly IM paliperidone in the place of the next scheduled injection and continue at monthly intervals. The two initiation doses are not required in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">When s<i>witching from injectable risperidone (Risperdal Consta) to monthly IM paliperidone the following recommendations have been made (Invega Sustenna Canadian product labeling 2015):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Risperdal Consta dose of 25 mg every 2 weeks, then IM paliperidone maintenance dose of 78 mg (as palmitate) or 50 mg (as base) monthly</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Risperdal Consta dose of 37.5 mg every 2 weeks, then IM paliperidone maintenance dose of 117 mg (as palmitate) or 75 mg (as base) monthly</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Risperdal Consta dose of 50 mg every 2 weeks, then IM paliperidone maintenance dose of 156 mg (as palmitate) or 100 mg (base) monthly</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Dosage adjustments:</i> Adjustments may be made monthly (full effect from adjustments may not be seen for several months)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Missed second initiation dose:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If &lt;4 weeks have elapsed since the first injection: Administer the missed dose 156 mg (as palmitate) or 100 mg (as base) in the deltoid as soon as possible, followed by a third dose of 117 mg (as palmitate) or 75 mg (as base) in either the deltoid or gluteal muscle 5 weeks after the first injection (regardless of when the second injection was administered), then begin normal monthly maintenance dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If &ge;4 weeks and &le;7 weeks have elapsed since the first injection: Administer a dose of 156 mg (as palmitate) or 100 mg (as base) in the deltoid as soon as possible, followed by another 156 mg dose (as palmitate) or 100 mg dose (as base) in the deltoid 1 week later, then begin normal monthly maintenance dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If &gt;7 weeks has elapsed since the first injection: Therapy must be reinitiated following dosing recommendations for initiation of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Missed maintenance dose:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If &ge;4 weeks and &le;6 weeks have elapsed since the last monthly injection: Administer the missed dose as soon as possible and continue therapy at monthly intervals.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If &gt;6 weeks and &le;6 months have elapsed since the last monthly injection:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If the maintenance dose was &lt;234 mg (as palmitate) or 150 mg (as base): Administer the same dose the patient was previously stabilized on in the deltoid as soon as possible, followed by a second equivalent dose in the deltoid 1 week later, then resume maintenance dose at monthly intervals.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If the maintenance dose was 234 mg (as palmitate) or 150 mg (as base): Administer a 156 mg dose (as palmitate) or 100 mg dose (as base) in the deltoid as soon as possible, followed by a second dose of 156 mg (as palmitate) or 100 mg dose (as base) in the deltoid 1 week later, then resume maintenance dose at monthly intervals.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If &gt;6 months have elapsed since last monthly maintenance injection: Therapy must be reinitiated following dosing recommendations for initiation of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Schizophrenia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Usual: 6 mg once daily (administered in the morning in clinical trials); titration not required, though some may benefit from lower or higher doses (range: 3 to 12 mg daily). If exceeding 6 mg daily, increases of 3 mg daily are recommended no more frequently than every 5 days, up to a maximum of 12 mg daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Injection:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Monthly paliperidone (Invega Sustenna): <b>Note:</b> Prior to initiation of monthly IM paliperidone, for patients na&iuml;ve to oral paliperidone or oral or injectable risperidone tolerability should be established with a test dose of oral paliperidone or oral risperidone. Previous oral antipsychotic regimen can be gradually discontinued at the time of initiation of monthly IM paliperidone. <b>Dosing based on paliperidone palmitate (US labeling) or paliperidone base (Canadian labeling).</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Initiation of therapy:</i></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Initial: 234 mg (as palmitate) or 150 mg (as base) on treatment day 1 followed by 156 mg (as palmitate) or 100 mg (as base) 1 week later with both doses administered in the deltoid muscle. The second dose may be administered 4 days before or after the weekly time point.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Maintenance: Following the 1-week initiation regimen, begin a maintenance dose of 117 mg (as palmitate) or 75 mg (as base) every month administered in either the deltoid or gluteal muscle. Some patients may benefit from higher or lower monthly maintenance doses (monthly maintenance dosage range: 39 to 234 mg [as palmitate] or 25 to 150 mg [as base]). The monthly maintenance dose may be administered 7 days before or after the monthly time point.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Conversion from oral paliperidone to IM paliperidone:</i></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Initiate IM therapy as described using the 1-week initiation regimen. Patients previously stabilized on oral doses can expect similar steady state exposure during maintenance treatment with IM therapy using the following conversion:</p>\n    <p style=\"text-indent:-2em;margin-left:14em;\">Oral extended-release dose of 12 mg daily, then IM maintenance dose of 234 mg (as palmitate) or 150 mg (as base) monthly</p>\n    <p style=\"text-indent:-2em;margin-left:14em;\">Oral extended-release dose of 9 mg daily, then IM maintenance dose of 156 mg (as palmitate) or 100 mg (as base) monthly</p>\n    <p style=\"text-indent:-2em;margin-left:14em;\">Oral extended-release dose of 6 mg daily, then IM maintenance dose of 117 mg (as palmitate) or 75 mg (as base) monthly</p>\n    <p style=\"text-indent:-2em;margin-left:14em;\">Oral extended-release dose of 3 mg daily, then IM maintenance dose of 39 to 78 mg (as palmitate) or 25 to 50 mg (as base) monthly</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Conversion from other oral antipsychotics to IM paliperidone:</i> There is no systematically collected data to address switching patients from other oral antipsychotics to IM paliperidone.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Switching from other long-acting injectable antipsychotics (at steady-state) to IM paliperidone:</i> Initiate IM paliperidone in the place of the next scheduled injection and continue at monthly intervals. The two initiation doses are not required in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">When switching<i> from injectable risperidone (Risperdal Consta) to monthly IM paliperidone the following recommendations have been made (Invega Sustenna Canadian product labeling 2015):</i></p>\n    <p style=\"text-indent:-2em;margin-left:14em;\">Risperdal Consta dose of 25 mg every 2 weeks, then IM paliperidone maintenance dose of 50 mg (as base) monthly</p>\n    <p style=\"text-indent:-2em;margin-left:14em;\">Risperdal Consta dose of 37.5 mg every 2 weeks, then IM paliperidone maintenance dose of 75 mg (as base) monthly</p>\n    <p style=\"text-indent:-2em;margin-left:14em;\">Risperdal Consta dose of 50 mg every 2 weeks, then IM paliperidone maintenance dose of 100 mg (as base) monthly</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Dosage adjustments:</i> Adjustments may be made monthly (full effect from adjustments may not be seen for several months)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Missed second initiation dose:</i></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">If &lt;4 weeks have elapsed since the first injection: Administer the missed dose (156 mg [as palmitate] or 100 mg [as base]) in the deltoid as soon as possible, followed by a third dose of 117 mg (as palmitate) or 75 mg (as base) in either the deltoid or gluteal muscle 5 weeks after the first injection (regardless of when the second injection was administered), then begin normal monthly maintenance dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">If &ge;4 weeks and &le;7 weeks have elapsed since the first injection: Administer a dose of 156 mg (as palmitate) or 100 mg (as base) in the deltoid as soon as possible, followed by another 156 mg dose (as palmitate) or 100 mg dose (as base) in the deltoid 1 week later, then begin normal monthly maintenance dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">If &gt;7 weeks have elapsed since the first injection: Therapy must be reinitiated following dosing recommendations for initiation of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Missed maintenance dose:</i></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">If &ge;4 weeks and &le;6 weeks have elapsed since the last monthly injection: Administer the missed dose as soon as possible and continue therapy at monthly intervals.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">If &gt;6 weeks and &le;6 months have elapsed since the last monthly injection:</p>\n    <p style=\"text-indent:-2em;margin-left:14em;\">If the maintenance dose was &lt;234 mg (as palmitate) or &lt;150 mg (as base): Administer the same dose the patient was previously stabilized on in the deltoid as soon as possible, followed by a second equivalent dose in the deltoid 1 week later, then resume maintenance dose at monthly intervals.</p>\n    <p style=\"text-indent:-2em;margin-left:14em;\">If the maintenance dose was 234 mg (as palmitate) or 150 mg (as base): Administer a 156 mg dose (as palmitate) or 100 mg dose (as base) in the deltoid as soon as possible, followed by a second dose of 156 mg (as palmitate) or 100 mg (as base) in the deltoid 1 week later, then resume maintenance dose at monthly intervals.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">If &gt;6 months have elapsed since last monthly maintenance injection: Therapy must be reinitiated following dosing recommendations for initiation of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Three-month paliperidone (Invega Trinza): <b>Note:</b> Three-month IM paliperidone is to be used only after monthly IM paliperidone (Invega Sustenna) has been established as adequate treatment for at least 4 months. The last 2 doses of monthly IM paliperidone should be the same dosage strength before starting 3-month IM paliperidone.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Conversion from monthly injection to 3-month injection:</i> Initiate 3-month IM paliperidone when the next monthly IM paliperidone dose is scheduled. Base the 3-month dose on the previous monthly dose, using the equivalent 3.5 times higher dose. Three-month IM paliperidone may be administered up to 7 days before or after the next monthly dose date. Following the initial injection, administer every 3 months. Patients may be given the injection up to 2 weeks before or after the 3-month time point. Conversion from monthly IM paliperidone (Invega Sustenna) 39 mg (as palmitate) or 25 mg (as base) to 3-month IM paliperidone (Invega Trinza) has not been studied.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Monthly IM paliperidone (Invega Sustenna) 78 mg (as palmitate) or 50 mg (as base) = 3-month IM paliperidone (Invega Trinza) 273 mg (as palmitate) or 175 mg (as base)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Monthly IM paliperidone (Invega Sustenna) 117 mg (as palmitate) or 75 mg (as base) = 3-month IM paliperidone (Invega Trinza) 410 mg (as palmitate) or 263 mg (as base)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Monthly IM paliperidone (Invega Sustenna) 156 mg (as palmitate) or 100 mg (as base) = 3-month IM paliperidone (Invega Trinza) 546 mg (as palmitate) or 350 mg (as base)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Monthly IM paliperidone (Invega Sustenna) 234 mg (as palmitate) or 150 mg (as base) = 3-month IM paliperidone (Invega Trinza) 819 mg (as palmitate) or 525 mg (as base)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Conversion from 3-month IM paliperidone to monthly IM paliperidone:</i> Initiate monthly IM paliperidone when the next 3-month IM paliperidone dose is scheduled. Base the monthly dose on the previous 3-month dose, using the equivalent 3.5 times lower dose. Following the initial injection, administer once monthly.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">3-month IM paliperidone (Invega Trinza) 273 mg (as palmitate) or 175 mg (as base) = Monthly IM paliperidone (Invega Sustenna) 78 mg (as palmitate) or 50 mg (as base)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">3-month IM paliperidone (Invega Trinza) 410 mg (as palmitate) or 263 mg (as base) = Monthly IM paliperidone (Invega Sustenna) 117 mg (as palmitate) or 75 mg (as base)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">3-month IM paliperidone (Invega Trinza) 546 mg (as palmitate) or 350 mg (as base) = Monthly IM paliperidone (Invega Sustenna) 156 mg (as palmitate) or 100 mg (as base)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">3-month IM paliperidone (Invega Trinza) 819 mg (as palmitate) or 525 mg (as base) = Monthly IM paliperidone (Invega Sustenna) 234 mg (as palmitate) or 150 mg (as base)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Conversion from 3-month IM paliperidone to paliperidone extended-release tablets:</i> Initiate paliperidone extended release tablets 3 months after the last dose of 3-month IM paliperidone. Base the once daily extended-release tablet dose on the last 3-month injection dose and weeks since last administered. Use the following conversion.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">If the last 3-month IM paliperidone dose was:</p>\n    <p style=\"text-indent:-2em;margin-left:14em;\">273 mg (as palmitate) or 175 mg (as base): 3 months to &gt;24 weeks since the last dose = 3 mg paliperidone extended-release tablets</p>\n    <p style=\"text-indent:-2em;margin-left:14em;\">410 mg (as palmitate) or 263 mg (as base):</p>\n    <p style=\"text-indent:-2em;margin-left:16em;\">3 months to 24 weeks since the last dose = 3 mg paliperidone extended-release tablets</p>\n    <p style=\"text-indent:-2em;margin-left:16em;\">&gt;24 weeks since the last dose = 6 mg paliperidone extended-release tablets</p>\n    <p style=\"text-indent:-2em;margin-left:14em;\">546 mg (as palmitate) or 350 mg (as base):</p>\n    <p style=\"text-indent:-2em;margin-left:16em;\">3 months to 18 weeks since the last dose = 3 mg paliperidone extended-release tablets</p>\n    <p style=\"text-indent:-2em;margin-left:16em;\">&gt;18 weeks to 24 weeks since the last dose = 6 mg paliperidone extended-release tablets</p>\n    <p style=\"text-indent:-2em;margin-left:16em;\">&gt;24 weeks since the last dose = 9 mg paliperidone extended-release tablets</p>\n    <p style=\"text-indent:-2em;margin-left:14em;\">819 mg (as palmitate) or 525 mg (as base):</p>\n    <p style=\"text-indent:-2em;margin-left:16em;\">3 months to 18 weeks since the last dose = 6 mg paliperidone extended-release tablets</p>\n    <p style=\"text-indent:-2em;margin-left:16em;\">&gt;18 weeks to 24 weeks since the last dose = 9 mg paliperidone extended-release tablets</p>\n    <p style=\"text-indent:-2em;margin-left:16em;\">&gt;24 weeks since the last dose = 12 mg paliperidone extended-release tablets</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Dosage adjustments:</i> Dosage adjustments can be made every 3 months in increments within the range of 273 to 819 mg (as palmitate) or 175 to 525 mg (as base) based on response and tolerability. Due to the long-acting nature, the patient's response to an adjusted dose may not be apparent for several months.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Missed dose 3 &frac12; months to 4 months since last injection:</i> Administer the previous 3-month dose as soon as possible and continue with normal dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Missed dose 4 months to 9 months since last injection:</i> Do not administer the next 3-month dose. If the last 3-month dose was:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">273 mg (as palmitate) or 175 mg (as base): Administer 78 mg (as palmitate) or 50 mg (as base) of monthly IM paliperidone (Invega Sustenna) into the deltoid muscle. Repeat same dose of monthly IM paliperidone (Invega Sustenna) one week later. One month following the second injection, administer 273 mg (as palmitate) or 175 mg (as base) of 3-month IM paliperidone (Invega Trinza) into the deltoid or gluteal muscle and resume normal dosing at 3-month intervals.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">410 mg (as palmitate) or 263 mg (as base): Administer 117 mg (as palmitate) or 75 mg (as base) of monthly IM paliperidone (Invega Sustenna) into the deltoid muscle. Repeat same dose of monthly IM paliperidone (Invega Sustenna) one week later. One month following the second injection, administer 410 mg (as palmitate) or 263 mg (as base) of 3-month IM paliperidone (Invega Trinza) into the deltoid or gluteal muscle and resume normal dosing at 3-month intervals.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">546 mg (as palmitate) or 350 mg (as base): Administer 156 mg (as palmitate) or 100 mg (as base) of monthly IM paliperidone (Invega Sustenna) into the deltoid muscle. Repeat same dose of monthly IM paliperidone (Invega Sustenna) one week later. One month following the second injection, administer 546 mg (as palmitate) or 350 mg (as base) of 3-month IM paliperidone (Invega Trinza) into the deltoid or gluteal muscle and resume normal dosing at 3-month intervals.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">819 mg (as palmitate) or 525 mg (as base): Administer 156 mg (as palmitate) or 100 mg (as base) of monthly IM paliperidone (Invega Sustenna) into the deltoid muscle. Repeat same dose of monthly IM paliperidone (Invega Sustenna) one week later. One month following the second injection, administer 819 mg (as palmitate) or 525 mg (as base) of 3-month IM paliperidone (Invega Trinza) into the deltoid or gluteal muscle and resume normal dosing at 3-month intervals.</p>\n    <p style=\"text-indent:-4em;margin-left:12em;\">\n      <i>Missed dose longer than 9 months since last injection:</i> Re-initiate treatment with monthly IM paliperidone (Invega Sustenna). Three-month IM paliperidone can be resumed after the patient has been adequately treated with monthly IM paliperidone for at least 4 months.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Delusional infestation (also called delusional parasitosis) (off-label use):</b> Oral: Initial: 3 mg daily; adjust dose based on response and tolerability up to 9 mg/day. Responses to therapy commonly observed after 2 weeks with maximal effect after 4 weeks (Albayrak 2011; Altinoz 2014; Freudenamnn 2009). Additional data may be necessary to further define the role of paliperidone in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Discontinuation of therapy</b>: American Psychiatric Association (APA), Canadian Psychiatric Association (CPA), and World Federation of Societies of Biological Psychiatry (WFSBP) guidelines recommend gradually tapering antipsychotics to avoid withdrawal symptoms and minimize the risk of relapse (APA [Lehman 2004]; Cerovecki 2013; CPA [Addington 2005]; WFSBP [Hasan 2012]); risk for withdrawal symptoms may be highest with highly anti-cholinergic or dopaminergic antipsychotics (Cerovecki 2013). When stopping antipsychotic therapy in patients with schizophrenia, the CPA guidelines recommend a gradual taper over 6 to 24 months, and the APA guidelines recommend reducing the dose by 10% each month (APA [Lehman 2004]; CPA [Addington 2005]). Continuing anti-parkinsonism agents for a brief period after discontinuation may prevent withdrawal symptoms (Cerovecki 2013). When switching antipsychotics, 3 strategies have been suggested: Cross-titration (gradually discontinuing the first antipsychotic while gradually increasing the new antipsychotic), overlap and taper (maintaining the dose of the first antipsychotic while gradually increasing the new antipsychotic, then tapering the first antipsychotic), and abrupt change (abruptly discontinuing the first antipsychotic and either increasing the new antipsychotic gradually or starting it at a treatment dose). Evidence supporting ideal switch strategies and taper rates is limited, and results are conflicting (Cerovecki 2013; Remington 2005).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12761050\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=paliperidone-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Paliperidone: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Schizophrenia: </b>Adolescents 12 to 17 years: Oral: Initial: 3 mg once daily; titration not required (no known benefit to efficacy from higher doses [ie, 6 mg daily for patients &lt;51 kg and 12 mg daily for patients &ge;51 kg]). If exceeding 3 mg daily, increases of 3 mg daily are recommended no more frequently than every 5 days.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3982411\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing; use with caution. Additional monitoring of renal function and orthostatic blood pressure may be warranted.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Psychosis/agitation associated with dementia (off-label use):</b> Oral: Initial: One-third to one-half the usual dose to treat psychosis in younger adults <b>or</b> the smallest available dosage. In patients without a clinically significant response after 4 weeks, taper and withdraw therapy. In patients with an adequate response, attempt to taper and withdraw therapy within 4 months, unless symptoms recurred with a previous taper attempt. Assess symptoms at least monthly during taper and for at least 4 months after withdrawal of therapy (APA [Reus 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3982412\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Clearance is decreased in renal impairment; adjust dose according to renal function:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild impairment (CrCl 50 to 79 mL/minute): Initial dose: 3 mg once daily; maximum dose: 6 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Moderate to severe impairment (CrCl 10 to 49 mL/minute): Initial dose: 1.5 mg once daily; maximum dose: 3 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment (CrCl &lt;10 mL/minute): Use not recommended (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild impairment (CrCl 50 to 79 mL/minute):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Monthly IM paliperidone (Invega Sustenna): Initiation of therapy: 156 mg (as palmitate) or 100 mg (as base) on treatment day 1, followed by 117 mg (as palmitate) or 75 mg (as base) 1 week later with both doses administered in the deltoid, followed by a maintenance dose of 78 mg (as palmitate) or 50 mg (as base) every month (administered in the deltoid or gluteal muscle)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Three-month IM paliperidone (Invega Trinza): Adjust dosage and stabilize the patient using the monthly IM injection, then transition to the 3-month IM injection. <b>Note:</b> Monthly IM paliperidone (Invega Sustenna) 78 mg (as palmitate) or 50 mg (as base) = 3-month IM paliperidone (Invega Trinza) 273 mg (as palmitate) or 175 mg (as base).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Moderate to severe impairment (CrCl &lt;50 mL/minute): Use not recommended</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3982413\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Oral, IM (monthly, 3- month):</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild to moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe impairment: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3982430\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Intramuscular, as palmitate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Invega Sustenna: 39 mg/0.25 mL (0.25 mL); 78 mg/0.5 mL (0.5 mL); 117 mg/0.75 mL (0.75 mL); 156 mg/mL (1 mL); 234 mg/1.5 mL (1.5 mL) [contains polyethylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Invega Trinza: 410 mg/1.315 mL (1.315 mL); 273 mg/0.875 mL (0.875 mL); 546 mg/1.75 mL (1.75 mL); 819 mg/2.625 mL (2.625 mL) [contains polyethylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Invega: 1.5 mg, 3 mg, 6 mg, 9 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1.5 mg, 3 mg, 6 mg, 9 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3981434\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5950134\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suspension, Intramuscular, as palmitate [strength expressed as base]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Invega Sustenna: 50 mg/0.5 mL (0.5 mL), 75 mg/0.75 mL (0.75 mL), 100 mg/1 mL (1 mL), 150 mg/1.5 mL (1.5 mL) [contains polyethylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Invega Trinza: 175 mg/0.875 mL; 263 mg/1.315 mL; 350 mg/1.75 mL; 525 mg/2.625 mL [contains polyethylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet Extended Release 24 Hour, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Invega: 3 mg, 6 mg, 9 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3982415\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer without regard to meals. Extended release tablets should be swallowed whole with liquids; do not crush, chew, or divide.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM injection: Administer by IM route only as a single injection (do not divide); do not administer by any other route. Avoid inadvertent injection into vasculature.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Monthly paliperidone (Invega Sustenna): Do not mix with any other product or diluent. Prior to injection, shake syringe for <b>at least 10 seconds</b> to ensure a homogenous suspension. Administer using only the needles that are provided in the kit. The 2 initial injections should be administered in the deltoid muscle using a 1<sup>1</sup>/<sub>2</sub> inch, 22-gauge needle for patients &ge;90 kg, and a 1 inch, 23-gauge needle for patients &lt;90 kg. The 2 initial deltoid intramuscular injections help attain therapeutic concentrations rapidly. Alternate deltoid injections (right and left deltoid muscle). The second dose may be administered 4 days before or after the weekly time point. Monthly maintenance doses can be administered in either the deltoid or gluteal muscle. Administer injections in the gluteal muscle using a 1<sup>1</sup>/<sub>2</sub> inch, 22-gauge needle (regardless of patient weight) in the upper-outer quadrant of the gluteal area. Alternate gluteal injections (right and left gluteal muscle). The monthly maintenance dose may be administered 7 days before or after the monthly time point.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Three-month paliperidone (Invega Trinza): Prior to injection, shake syringe for with tip pointing up <b>at least 15 seconds</b> to ensure a homogenous suspension. <b>Inject within 5 minutes of shaking vigorously.</b> Inject slowly, deep into the deltoid or gluteal muscle. Must be administered using only the thin wall needles that are provided in the pack. Do <b>not</b> use needles from monthly IM paliperidone or other commercially-available needles to reduce the risk of blockage. Administer into the center of the deltoid muscle using a 1<sup>1</sup>/<sub>2</sub> inch, 22-gauge thin wall needle for patients &ge;90 kg, and a 1 inch, 22-gauge thin wall needle for patients &lt;90 kg. Alternate deltoid injections (right and left deltoid muscle). Administer injections in the gluteal muscle using a 1<sup>1</sup>/<sub>2</sub> inch, 22-gauge thin wall needle (regardless of patient weight) in the upper-outer quadrant of the gluteal area. Alternate gluteal injections (right and left gluteal muscle). In the event of an incompletely administered dose, do not re-inject the dose remaining in the syringe and do not administer another dose. Closely monitor and treat the patient with oral supplementation as clinically appropriate until the next scheduled 3-month injection.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49133437\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. For IM preparation, NIOSH recommends double gloving, a protective gown, and ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator). Double gloving and a protective gown are required during IM administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3982377\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Schizophrenia:</b> Treatment of schizophrenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Schizoaffective disorder (oral and monthly IM paliperidone):</b> Treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers or antidepressants</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25744719\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Delusional infestation (also called delusional parasitosis); Psychosis/agitation associated with dementia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14087817\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Invega may be confused with Intuniv</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Antipsychotics are identified in the Beers Criteria  as potentially inappropriate medications to be avoided in patients 65 years and older with dementia due to an increased risk of mortality, cerebrovascular accidents (stroke), and a greater rate of cognitive decline with use; avoid antipsychotics for behavioral problems associated with dementia or delirium unless alternative nonpharmacologic therapies have failed and patient may harm self or others. Use <i>may be appropriate</i> in geriatric patients with schizophrenia, bipolar disorder, or for short-term use as an antiemetic during chemotherapy. In addition, antipsychotics should be used with caution in older adults due to their potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3982386\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Unless otherwise noted, frequency of adverse effects is reported for the oral/IM formulation in adults. Frequency not always defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Tachycardia (adolescents and adults: &le;14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Extrapyramidal reaction (adolescents: 4% to 40%; adults: &le;3% to 26%; dose dependent), drowsiness (adolescents: 9% to 26%; adults: 4% to 12%; dose dependent), parkinsonian-like syndrome (adolescents and adults: 3% to 18%; dose dependent), akathisia (adolescents and adults: 4% to 17%; dose dependent), headache (adolescents and adults: 6% to 15%), dystonia (adolescents and adults: 1% to 14%; dose dependent)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Decreased HDL cholesterol (adolescents and adults: 14% to 29%), weight gain (adolescents and adults; &ge;7% from baseline: 2% to 19%), abnormal triglycerides (adolescents and adults: 5% to 13%), altered serum glucose (adolescents and adults: 4% to 11%), blood cholesterol abnormal (adolescents and adults: 4% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Vomiting (adolescents and adults: 5% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Change in LDL (adolescents and adults: 4% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Hyperkinesia (adolescents and adults: 4% to 17%; dose dependent), tremor (adolescents and adults: 1% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Orthostatic hypotension (2% to 4%; dose dependent), bundle branch block (&le;3%), first degree atrioventricular block (2%), hypertension (&le;2%), sinus arrhythmia (&le;2%), bradycardia (adolescents and adults: &lt;2%), edema (adolescents and adults: &lt;2%), palpitations (adolescents and adults: &lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Agitation (&le;10%), anxiety (adolescents and adults: &le;9%), dizziness (adolescents and adults: 2% to 6%), dysarthria (1% to 4%; dose dependent), fatigue (adolescents and adults: 4%), lethargy (adolescents: &le;3%), sleep disorder (&le;3%), nightmares (&le;2%), insomnia (adolescents and adults: &lt;2%), opisthotonus (adolescents and adults: &lt;2%), tonic-clonic seizures</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (adolescents and adults: &lt;2%), skin rash (adolescents and adults: &lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Amenorrhea (adolescents and adults: &le;6%), galactorrhea (adolescents and adults: &le;4%), gynecomastia (adolescents and adults: &le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (4% to 8%), dyspepsia (5% to 6%), sialorrhea (adolescents and adults: &le;6%; dose dependent), constipation (4% to 5%), abdominal pain (&le;2% to 4%), increased appetite (2% to 3%), toothache (2% to 3%), xerostomia (adolescents and adults: 2% to 3%), diarrhea (&le;3%), swollen tongue (adolescents: &le;3%), stomach discomfort (2%), decreased appetite (1% to 2%), flatulence (adolescents and adults: &lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (&le;3%), retrograde ejaculation (adolescents and adults:&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT (adolescents and adults: &lt;2%), increased serum AST (adolescents and adults: &lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Anaphylaxis (adolescents and adults: &lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction (3% to 10%), erythema at injection site (&le;2%), swelling at injection site (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Dyskinesia (adolescents and adults: &lt;1% to 9%), myalgia (&le;4%; dose dependent), weakness (adolescents and adults: &le;4%), back pain (1% to 3%), limb pain (&le;3%), tongue paralysis (adolescents: &le;3%), stiffness (2%), arthralgia (adolescents and adults: &lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blurred vision (adolescents and adults: &le;3%), abnormal eye movements (adolescents and adults: &lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection (2% to 10%), nasopharyngitis (adolescents and adults: 2% to 5%; dose dependent), cough (2% to 3%; dose dependent), rhinitis (1% to 3%; dose dependent), pharyngolaryngeal pain (1% to 2%; dose dependent), epistaxis (&le;2%), nasal congestion (adolescents and adults: &lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Cerebrovascular accident, hypotension, ischemia, peripheral edema, postural orthostatic tachycardia, prolonged Q-T interval on ECG, transient ischemic attacks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Drooling, hypertonia, psychomotor agitation, restlessness, seizure, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Papular rash</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Menstrual disease</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Intestinal obstruction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Breast disease (includes discharge, engorgement, pain, tenderness), erectile dysfunction, sexual disorder</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Neck stiffness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Oculogyric crisis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Aspiration pneumonia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abnormal gait, abscess at injection site, agranulocytosis, alopecia, angioedema, antiemetic effect, atrial fibrillation, bradykinesia, cellulitis at injection site, cogwheel rigidity, deep vein thrombosis, diabetes mellitus, diabetic ketoacidosis, dysgeusia, ECG abnormality, granulocytopenia, gynecomastia, hyperglycemia, hyperinsulinism, hyperprolactinemia, hypersensitivity, hypoglycemia, hypothermia, intraoperative floppy iris syndrome, jaundice, lethargy, leukopenia, mania, muscle spasm, muscle twitching, musculoskeletal pain, neuroleptic malignant syndrome, neutropenia, orthostatic dizziness, pancreatitis, priapism, pulmonary embolism, sedation, SIADH, sleep apnea, syncope, tardive dyskinesia, thrombocytopenia, thrombotic thrombocytopenic purpura, torticollis, trismus, urinary incontinence, urinary retention, urticaria, venous thromboembolism, water intoxication</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3982382\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to paliperidone, risperidone, or any component of the formulation </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3982383\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered cardiac conduction: May alter cardiac conduction and prolong the QTc interval; life-threatening arrhythmias have occurred with therapeutic doses of antipsychotics (Ray 2009). Risk may be increased by conditions or concomitant medications which cause bradycardia, hypokalemia, and/or hypomagnesemia. Avoid use in combination with QTc-prolonging drugs. Avoid use in patients with congenital long QT syndrome and in patients with history of cardiac arrhythmia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antiemetic effects: May mask toxicity of other drugs or conditions (eg, intestinal obstruction, Reye's syndrome, brain tumor) due to antiemetic effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Blood dyscrasias: Leukopenia, neutropenia, and agranulocytosis (sometimes fatal) have been reported in clinical trials and postmarketing reports with antipsychotic use; presence of risk factors (eg, preexisting low WBC or ANC or history of drug-induced leuko-/neutropenia) should prompt periodic blood count assessment. Monitor patients with clinically significant neutropenia for a fever or other signs of infection, and discontinue therapy if absolute neutrophil count &lt;1,000/mm<sup>3</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cerebrovascular effects: An increased incidence of cerebrovascular adverse effects (eg, transient ischemic attack, stroke), including fatalities, has been reported in placebo-controlled trials of risperidone (paliperidone is the primary active metabolite of risperidone) for the unapproved use in elderly patients with dementia-related psychosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dyslipidemia: Increased cholesterol and triglycerides and decreased HDL have been noted. Use with caution in patients with a pre-existing abnormal lipid profile.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Esophageal dysmotility/aspiration: Antipsychotic use has been associated with esophageal dysmotility and aspiration; use with caution in patients at risk of aspiration pneumonia (eg, Alzheimer disease). Do not use in patients unable to swallow the tablet whole.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extrapyramidal symptoms: May cause extrapyramidal symptoms (EPS), including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia (risk of these reactions is generally much lower relative to typical/conventional antipsychotics; frequencies reported are similar to placebo). Risk of dystonia (and probably other EPS) may be greater with increased doses, use of conventional antipsychotics, males, and younger patients. Factors associated with greater vulnerability to tardive dyskinesia include older in age, female gender combined with postmenopausal status, Parkinson disease, pseudoparkinsonism symptoms, affective disorders (particularly major depressive disorder), concurrent medical diseases such as diabetes, previous brain damage, alcoholism, poor treatment response, and use of high doses of antipsychotics (APA [Lehman 2004]; Soares-Weiser 2007). Consider therapy discontinuation with signs/symptoms of tardive dyskinesia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Falls: May increase the risk for falls due to somnolence, orthostatic hypotension, and motor or sensory instability. Complete fall risk assessments at baseline and periodically during treatment in patients with diseases or on medications that may also increase fall risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperglycemia: Atypical antipsychotics have been associated with development of hyperglycemia; in some cases, may be extreme and associated with ketoacidosis, hyperosmolar coma, or death. All patients should be monitored for symptoms of hyperglycemia (eg, polydipsia, polyuria, polyphagia, weakness). Use with caution in patients with diabetes (or risk factors) or other disorders of glucose regulation; monitor for worsening of glucose control. Patients with risk factors for diabetes (eg, obesity or family history) should have a baseline fasting blood sugar (FBS) and periodically during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperprolactinemia: Use is associated with increased prolactin levels; clinical significance of hyperprolactinemia in patients with breast cancer or other prolactin-dependent tumors is unknown.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intraoperative floppy iris syndrome (IFIS): Few case reports describe IFIS in patients receiving risperidone and undergoing cataract surgery (Ford, 2011). IFIS has not been reported with paliperidone but caution is advised since it is the active metabolite of risperidone. Prior to cataract surgery, evaluate for prior or current paliperidone or risperidone use. The benefits or risks of interrupting paliperidone or risperidone prior to surgery have not been established; clinicians are advised to proceed with surgery cautiously.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuroleptic malignant syndrome (NMS): Use may be associated with NMS; monitor for mental status changes, fever, muscle rigidity, and/or autonomic instability (risk may be increased in patients with Parkinson disease or Lewy body dementia).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Orthostatic hypotension: May cause orthostatic hypotension and syncope; use with caution in patients with known cardiovascular disease (heart failure, history of myocardial infarction or ischemia, conduction abnormalities), cerebrovascular disease, or conditions that predispose the patient to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Priapism: Rare cases of priapism have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Suicidal ideation: The possibility of a suicide attempt is inherent in psychotic illness or bipolar disorder; use with caution in high-risk patients during initiation of therapy. Prescriptions should be written for the smallest quantity consistent with good patient care.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Temperature regulation: Impaired core body temperature regulation may occur; caution with strenuous exercise, heat exposure, dehydration, and concomitant medication possessing anticholinergic effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Weight gain: Significant weight gain has been observed with antipsychotic therapy; incidence varies with product. Monitor waist circumference and BMI.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dementia: <b>[US Boxed Warning]: Elderly patients with dementia-related psychosis treated with antipsychotics are at an increased risk of death compared to placebo.</b> Most deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Use with caution in patients with Lewy body dementia or Parkinson disease dementia due to greater risk of adverse effects, increased sensitivity to extrapyramidal effects, and association with irreversible cognitive decompensation or death. (APA [Reus 2016]). Paliperidone is not approved for the treatment of dementia-related psychosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Parkinson disease: Use with caution in patients with Parkinson disease; may be more sensitive to CNS-related and extrapyramidal effects. Antipsychotics may aggravate motor disturbances in patients with Parkinson disease (APA [Lehman 2004]; APA [Reus 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with mild renal disease; dosage reduction is recommended. Not recommended in patients with moderate to severe impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold. Elderly patients may be at increased risk of seizures due to an increased prevalence of predisposing factors.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extended-release tablet: Use is not recommended in patients with preexisting severe gastrointestinal narrowing disorders (nondeformable controlled release formulation). Patients with upper GI tract alterations in transit time may have increased or decreased bioavailability of paliperidone. Formulation consists of drug within a nonabsorbable shell; following drug release/absorption, the shell is expelled in the stool.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>\n          <b>Other warnings/precautions</b>:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation of therapy: When discontinuing antipsychotic therapy, the American Psychiatric Association (APA), Canadian Psychiatric Association (CPA), and World Federation of Societies of Biological Psychiatry (WFSBP) guidelines recommend gradually tapering antipsychotics to avoid physical withdrawal symptoms, including anorexia, anxiety, diaphoresis, diarrhea, dizziness, dyskinesia, headache, myalgia, nausea, paresthesia, restlessness, tremulousness, and vomiting (APA [Lehman 2004]; CPA [Addington 2005]; Lambert 2007; WFSBP [Hasan 2012]). The risk of withdrawal symptoms is highest following abrupt discontinuation of highly anti-cholinergic or dopaminergic antipsychotics (Cerovecki 2013). Additional factors such as duration of antipsychotic exposure, the indication for use, medication half-life, and risk for relapse should be considered. In schizophrenia, there is no reliable indicator to differentiate the minority who will not from the majority who will relapse with drug discontinuation. However, studies in which the medication of well-stabilized patients were discontinued indicate that 75% of patients relapse within 6 to 24 months. Indefinite maintenance antipsychotic medication is generally recommended, and especially for patients who have had multiple prior episodes or 2 episodes within 5 years (APA [Lehman 2004]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9838448\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of P-glycoprotein/ABCB1</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3982393\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10174&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors (Central): May enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amisulpride: Antipsychotic Agents may enhance the adverse/toxic effect of Amisulpride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: Antipsychotic Agents may diminish the stimulatory effect of Amphetamines. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anti-Parkinson Agents (Dopamine Agonist): Antipsychotic Agents (Second Generation [Atypical]) may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).  Management: Consider using an alternative antipsychotic agent when possible in patients with Parkinson disease.  If an atypical antipsychotic is necessary, consider using clozapine or quetiapine, which may convey the lowest interaction risk.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bilastine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May decrease the serum concentration of Paliperidone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: Antipsychotic Agents may diminish the therapeutic effect of Guanethidine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indapamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Inducers of CYP3A4 (Strong) and P-glycoprotein: May decrease the serum concentration of Paliperidone. Management: Avoid using the 3-month extended-release injectable suspension (Invega Trinza) with inducers of both CYP3A4 and P-glycoprotein during the 3-month dosing interval if possible. If combination is necessary, consider using extended-release tablets.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itraconazole: May enhance the QTc-prolonging effect of Paliperidone. Itraconazole may decrease the metabolism of Paliperidone.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. Lumacaftor may increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: Antipsychotic Agents may enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mizolastine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pefloxacin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: Antipsychotic Agents may diminish the therapeutic effect of Piribedil. Piribedil may diminish the therapeutic effect of Antipsychotic Agents.  Management: Use of piribedil with antiemetic neuroleptics is contraindicated, and use with antipsychotic neuroleptics, except for clozapine, is not recommended.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: Antipsychotic Agents may diminish the therapeutic effect of Quinagolide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RisperiDONE: May enhance the adverse/toxic effect of Paliperidone. Management: Additive paliperidone exposure is expected with this combination.  Consider using an alternative combination when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<b> Exceptions: </b>Nicergoline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of Paliperidone. Management: Avoid using the 3-month extended-release injectable suspension (Invega Trinza) with inducers of both CYP3A4 and P-glycoprotein during the 3-month dosing interval if possible. If combination is necessary, consider using extended-release tablets.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulpiride: Antipsychotic Agents may enhance the adverse/toxic effect of Sulpiride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teneligliptin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproate Products: May increase the serum concentration of Paliperidone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3982378\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3982379\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events have not been observed in animal reproduction studies. Antipsychotic use during the third trimester of pregnancy has a risk for extrapyramidal symptoms (EPS) and/or withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor. These effects may be self-limiting and allow recovery within hours or days with no specific treatment, or they may be severe requiring prolonged hospitalization.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Paliperidone may cause hyperprolactinemia, which may decrease reproductive function in both males and females. Paliperidone is the active metabolite of risperidone; refer to Risperidone monograph for additional information.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The ACOG recommends that therapy during pregnancy be individualized; treatment with psychiatric medications during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary healthcare provider, and pediatrician. Safety data related to atypical antipsychotics during pregnancy is limited and routine use is not recommended. However, if a woman is inadvertently exposed to an atypical antipsychotic while pregnant, continuing therapy may be preferable to switching to a typical antipsychotic that the fetus has not yet been exposed to; consider risk:benefit (ACOG 2008).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Healthcare providers are encouraged to enroll women 18 to 45 years of age exposed to paliperidone during pregnancy in the Atypical Antipsychotics Pregnancy Registry (1-866-961-2388 or http://www.womensmentalhealth.org/pregnancyregistry).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15588158\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Paliperidone is excreted in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3982417\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Mental status; vital signs (as clinically indicated); blood pressure (baseline; repeat 3 months after antipsychotic initiation, then yearly); weight, height, BMI, waist circumference (baseline; repeat at 4, 8, and 12 weeks after initiating or changing therapy, then quarterly; consider switching to a different antipsychotic for a weight gain &ge;5% of initial weight); CBC (as clinically indicated; monitor frequently during the first few months of therapy in patients with preexisting low WBC or history of drug-induced leukopenia/neutropenia); electrolytes, renal and liver function (annually and as clinically indicated); personal and family history of obesity, diabetes, dyslipidemia, hypertension, or cardiovascular disease (baseline; repeat annually); fasting plasma glucose level/HbA<sub>1c</sub> (baseline; repeat 3 months after starting antipsychotic, then yearly); fasting lipid panel (baseline; repeat 3 months after initiation of antipsychotic; if LDL level is normal repeat at 2- to 5-year intervals or more frequently if clinical indicated); changes in menstruation, libido, development of galactorrhea, erectile and ejaculatory function (at each visit for the first 12 weeks after the antipsychotic is initiated or until the dose is stable, then yearly); abnormal involuntary movements or parkinsonian signs (baseline; repeat weekly until dose stabilized for at least 2 weeks after introduction and for 2 weeks after any significant dose increase); tardive dyskinesia (every 12 months; high-risk patients every 6 months); ocular examination (yearly in patients &gt;40 years; every 2 years in younger patients) (ADA 2004; Lehman 2004; Marder 2004).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3982398\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Paliperidone is considered a benzisoxazole atypical antipsychotic as it is the primary active metabolite of risperidone. As with other atypical antipsychotics, its therapeutic efficacy is believed to result from mixed central serotonergic and dopaminergic antagonism. The addition of serotonin antagonism to dopamine antagonism (classic neuroleptic mechanism) is thought to improve negative symptoms of psychoses and reduce the incidence of extrapyramidal side effects (Huttunen 1995). Similar to risperidone, paliperidone demonstrates high affinity to &alpha;<sub>1</sub>, &alpha;<sub>2</sub>, D<sub>2</sub>, H<sub>1</sub>, and 5-HT<sub>2A</sub> receptors and low affinity for muscarinic receptors. In contrast to risperidone, paliperidone displays nearly 10-fold lower affinity for &alpha;<sub>2</sub> and 5-HT<sub>2A</sub> receptors, and nearly three- to fivefold less affinity for 5-HT<sub>1A</sub> and 5-HT<sub>1D</sub>, respectively.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3982400\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Note:</b> Pharmacokinetic parameters in adolescent patients weighing &gt;51 kg were similar to adults; an increased drug exposure (23%) was observed in adolescent patient weighing &lt;51 kg compared to adults and was not considered clinically significant. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: IM: Slow release (Monthly: Begins on day 1 and continues up to 126 days; 3-month: Begins on day 1 and continues up to 18 months)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: Oral: 487 L; Monthly IM: 391 L; 3-month IM: 1960 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 74% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic via CYP2D6 and 3A4 (limited role in elimination); minor metabolism (&lt;10% each) via dealkylation, hydroxylation, dehydrogenation, and benzisoxazole scission</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: 28%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: 23 hours; 24 to 51 hours with renal impairment (CrCl &lt;80 mL/minute)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Monthly IM (following a single-dose administration): Range: 25 to 49 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3-month IM: Deltoid injection range: 84 to 95 days; Gluteal injection range: 118 to 139 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: Oral: ~24 hours; Monthly IM: 13 days; 3-month IM: 30 to 33 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (80%; 59% as unchanged drug); feces (11%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5165183\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Invega Sustenna Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">39 mg/0.25 mL (0.25 mL): $500.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">78 mg/0.5 mL (0.5 mL): $1,000.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">117 mg/0.75 mL (0.75 mL): $1,500.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">156 mg/mL (1 mL): $2,001.41</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">234 mg/1.5 mL (1.5 mL): $3,002.03</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Invega Trinza Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">273MG/0.875ML (0.875 mL): $3,001.93</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">410MG/1.315ML (1.315 mL): $4,502.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">546MG/1.75ML (1.75 mL): $6,004.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">819MG/2.625ML (2.625 mL): $9,006.08</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Invega Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5 mg (30): $1,329.23</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 mg (30): $1,329.23</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 mg (30): $1,329.23</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">9 mg (30): $1,993.82</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Paliperidone ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5 mg (30): $916.86</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 mg (30): $916.86</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 mg (30): $916.86</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">9 mg (30): $1,375.29</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539984\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Inveda (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Inveda Sustenna (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Invega (AE, AR, AT, AU, BB, BE, BH, BR, CH, CN, CO, CY, CZ, DE, DK, EE, ES, GB, GR, HK, HR, ID, IE, IL, IS, IT, JO, JP, KR, KW, LB, LT, LU, MT, MY, NL, NZ, PH, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, TH, TR, TW, VN);</li>\n      <li>Invega SR (KR);</li>\n      <li>Invega Sustenna (AU, BR, CN, HK, ID, IL, JO, MY, NZ, PH, SG, TH, TW);</li>\n      <li>Inveha (UA);</li>\n      <li>Keplioon (JP);</li>\n      <li>Kseplion (UA);</li>\n      <li>Trevicta (IE);</li>\n      <li>Xeplion (CH, CY, CZ, DK, EE, ES, GB, HR, IE, IL, IS, LT, LU, LV, MT, NO, RO, SE, SI, SK, TR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24933737\"></a>Albayrak Y; Ekinci O; Ozbay SY. Primary delusional parasitosis treated effectively with paliperidone.<i> Israel Journal of Psychiatry &amp; Related Sciences.</i> 2011;48(4):291-292.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paliperidone-drug-information/abstract-text/24933737/pubmed\" target=\"_blank\" id=\"24933737\">24933737</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25147315\"></a>Altinoz AE; Tosun Altinoz S; Kucukkarapinar M; Cosar B. Paliperidone: another treatment option for delusional parasitosis. <i>Australasian Psychiatry.</i> 2014;22(6):576-578.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paliperidone-drug-information/abstract-text/25147315  /pubmed\" target=\"_blank\" id=\"25147315  \">25147315  </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists, ACOG Practice Bulletin: Clinical Management Guidelines for Obstetricians-Gynecologists No. 92 April 2008 (Replaces Practice Bulletin Number 87, November 2007), &ldquo;Use of Psychiatric Medications During Pregnancy and Lactation,&rdquo; <i>Obstet Gynecol</i>, 2008, 111(4):1001-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paliperidone-drug-information/abstract-text/18378767/pubmed\" target=\"_blank\" id=\"18378767\">18378767</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. <i>J Clin Psychiatry</i>. 2004;65(2):267-272.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paliperidone-drug-information/abstract-text/15003083/pubmed\" target=\"_blank\" id=\"15003083\">15003083</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi:10.1111/jgs.13702<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paliperidone-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Canadian Psychiatric Association. Clinical practice guidelines. Treatment of schizophrenia. <i>Can J Psychiatry</i>. 2005;50(13)(suppl 1):7S-57S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paliperidone-drug-information/abstract-text/16529334/pubmed\" target=\"_blank\" id=\"16529334\">16529334</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cerovecki A, Musil R, Klimke A, et al. Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. <i>CNS Drugs</i>. 2013;27(7):545-572. doi: 10.1007/s40263-013-0079-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paliperidone-drug-information/abstract-text/23821039/pubmed\" target=\"_blank\" id=\"23821039\">23821039</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dixon L, Perkins D, and Calmes C, <i>Guideline Watch (September 2009): Practice Guideline for the Treatment of Schizophrenia</i>, Arlington, Va: American Psychiatric Association, 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ford RL, Sallam A, Towler HM. Intraoperative floppy iris syndrome associated with risperidone intake. <i>Eur J Ophthalmol</i>. 2011;21(2):210-211.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paliperidone-drug-information/abstract-text/20853271/pubmed\" target=\"_blank\" id=\"20853271\">20853271</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19040517\"></a>Freudenmann RW, K&uuml;hnlein P, Lepping P, Sch&ouml;nfeldt-Lecuona C. Secondary delusional parasitosis treated with paliperidone. <i>Clin Exp Dermatol</i>. 2009;34(3):375-377.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paliperidone-drug-information/abstract-text/19040517 /pubmed\" target=\"_blank\" id=\"19040517 \">19040517 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hasan A, Falkai P, Wobrock T, et al; World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. <i>World J Biol Psychiatry</i>. 2012;13(5):318-378. doi: 10.3109/15622975.2012.696143.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paliperidone-drug-information/abstract-text/22834451/pubmed\" target=\"_blank\" id=\"22834451\">22834451</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gill SS, Bronskill SE, Normand SL, et al, &ldquo;Antipsychotic Drug Use and Mortality in Older Adults With Dementia,&rdquo; <i>Ann Intern Med</i>, 2007, 146(11):775-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paliperidone-drug-information/abstract-text/17548409/pubmed\" target=\"_blank\" id=\"17548409\">17548409</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Huttunen M. The evolution of the serotonin-dopamine antagonist concept. <i>J Clin Psychopharmacol</i>. 1995;15(1 Suppl 1):4S-10S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paliperidone-drug-information/abstract-text/7730499/pubmed\" target=\"_blank\" id=\"7730499\">7730499</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Invega (paliperidone) [prescribing information]. Titusville, NJ: Janssen; January 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Invega (paliperidone) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; February 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Invega Sustenna (paliperidone) [prescribing information]. Titusville, NJ: Janssen; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Invega Sustenna (paliperidone) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Invega Trinza (paliperidone) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Invega Trinza (paliperidone) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jung SM, Kim K-A, Cho H-K, et al, &ldquo;Cytochrome P450 3A Inhibitor Itraconazole Affects Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone in Schizophrenic Patients,&rdquo; <i>Clin Pharmacol Ther</i>, 2005, 78(5):520-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paliperidone-drug-information/abstract-text/16321618/pubmed\" target=\"_blank\" id=\"16321618\">16321618</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lambert TJ. Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes. <i>J Clin Psychiatry</i>. 2007;68(suppl 6):10-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paliperidone-drug-information/abstract-text/17650054/pubmed\" target=\"_blank\" id=\"17650054\">17650054</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lehman AF, Lieberman JA, Dixon LB, et al; American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. <i>Am J Psychiatry</i>. 2004;161(2)(suppl):1-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paliperidone-drug-information/abstract-text/15000267/pubmed\" target=\"_blank\" id=\"15000267\">15000267</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. <i>Am J Psychiatry</i>. 2004;161(8):1334-1349.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paliperidone-drug-information/abstract-text/15285957/pubmed\" target=\"_blank\" id=\"15285957\">15285957</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moore TA, &ldquo;Schizophrenia Treatment Guidelines in the United States,&rdquo; <i>Clin Schizophr Relat Psychoses</i>, 2011, 5(1):40-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paliperidone-drug-information/abstract-text/21459738/pubmed\" target=\"_blank\" id=\"21459738\">21459738</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. <i>N Engl J Med</i>. 2009;360(3):225-235. doi: 10.1056/NEJMoa0806994.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paliperidone-drug-information/abstract-text/19144938/pubmed\" target=\"_blank\" id=\"19144938\">19144938</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Remington G, Chue P, Stip E, Kopala L, Girard T, Christensen B. The crossover approach to switching antipsychotics: what is the evidence? <i>Schizophr Res</i>. 2005;76(2-3):267-272. doi: 10.1016/j.schres.2005.01.009.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paliperidone-drug-information/abstract-text/15949658/pubmed\" target=\"_blank\" id=\"15949658\">15949658</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reus VI, Fochtmann LJ, Eyler AE, et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry. 2016;173(5):543-546. http://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.2015.173501. Accessed May 26, 2016. doi: 10.1176/appi.ajp.2015.173501.27133416</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Richelson E and Souder T, &ldquo;Binding of Antipsychotic Drugs to Human Brain Receptors. Focus on Newer Generation Compounds,&rdquo; <i>Life Sci</i>, 2000, 68(1):29-39.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paliperidone-drug-information/abstract-text/11132243/pubmed\" target=\"_blank\" id=\"11132243\">11132243</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schneeweiss S, Setoguchi S, Brookhart A, et al, &ldquo;Risk of Death Associated With the Use of Conventional Versus Atypical Antipsychotic Drugs Among Elderly Patients,&rdquo; <i>CMAJ</i>, 2007, 176(5): 627-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paliperidone-drug-information/abstract-text/17325327/pubmed\" target=\"_blank\" id=\"17325327\">17325327</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Soares-Weiser K, Fernandez HH. Tardive dyskinesia. <i>Semin Neurol</i>. 2007;27(2):159-169.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paliperidone-drug-information/abstract-text/17390261/pubmed\" target=\"_blank\" id=\"17390261\">17390261</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spina E, Avenoso A, Facciola G, et al, &ldquo;Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone: Effect of Comedication with Carbamazepine or Valproate,&rdquo; <i>Ther Drug Monit</i>, 2000, 22:481-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paliperidone-drug-information/abstract-text/10942191/pubmed\" target=\"_blank\" id=\"10942191\">10942191</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10174 Version 212.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50629645\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709193\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F3981432\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F5941023\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F3982373\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F3982410\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F12761050\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F3982411\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F3982412\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F3982413\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F3982430\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F3981434\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F5950134\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F3982415\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49133437\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F3982377\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25744719\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F14087817\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F3982386\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F3982382\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F3982383\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F9838448\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F3982393\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F3982378\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F3982379\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F15588158\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F3982417\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F3982398\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F3982400\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F5165183\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539984\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10174|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=paliperidone-patient-drug-information\" class=\"drug drug_patient\">Paliperidone: Patient drug information</a></li><li><a href=\"topic.htm?path=paliperidone-pediatric-drug-information\" class=\"drug drug_pediatric\">Paliperidone: Pediatric drug information</a></li></ul></div></div>","javascript":null}